Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and accessibility. What’s keeping the pills from taking off?

In his suit, Todd Engel, of Howard County, accused Novo Nordisk Inc. and 10 other ... for the treatment of diabetes and chronic kidney disease. However, it is often prescribed or used for weight ...

A Maryland man with diabetes is suing Novo Nordisk, alleging that semaglutide ... heart failure, or chronic kidney disease patients on renin-angiotensin-aldosterone system (RAAS) inhibitors ...

Novo Nordisk (NVO) won a key case Thursday to stop ... compounded semaglutide — the active ingredient in diabetes drug Ozempic and weight-loss drug Wegovy — next month. That was the deadline ...

Ozempic use could result in billions in annual ... Also Read: Eli Lilly’s Zepbound Shows Superior Weight Loss Over Novo Nordisk’s Wegovy In Head-To-Head Trial In the U.K., 26.5% of adults ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 or 3 fibrosis.

In more recent news, FDA has approved Ozempic to reduce risk of kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Novo Nordisk also has introduced ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Novo Nordisk is pursuing new indications for semaglutide, including label expansions for Wegovy in additional cardiovascular conditions and for Ozempic in T2D patients with chronic kidney disease.